Please enable Javascript
Muscle Invasive Urothelial Carcinoma
Advertisement
Primary Analysis of Gemcitabine, Cisplatin Plus Neoadjuvant Durvalumab in MIBC
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
September 8, 2023
Perioperative durvalumab with gemcitabine/cisplatin in patients with resectable MIBC resulted in high EFS and OS at 2 years.
Read More
Precision Therapy for MIBC: Novel Treatments Helping, Biomarkers Lacking
Guru P. Sonpavde, MD
Muscle Invasive Urothelial Carcinoma
|
August 24, 2023
Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.
Read More
Real-world Association of Tumor-Informed MRD With Clinical Outcomes for MIBC
Ajitha Kommalapati, MD
ASCO 2023
|
August 15, 2023
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
View More
Dr. Raj Satkunasivam on Neoadjuvant Sasanlimab and SBRT for Cisplatin-Ineligible MIBC
Raj Satkunasivam, MD, MS, FRCSC
Muscle Invasive Urothelial Carcinoma
|
August 9, 2023
Dr. Satkunasivam details the RAD VACCINE MIBC trial, an evaluation of the efficacy and safety of neoadjuvant sasanlimab.
View More
Dr. Raj Satkunasivam on MIBC Neoadjuvant Approaches for Local, Distant Control
Raj Satkunasivam, MD, MS, FRCSC
Muscle Invasive Urothelial Carcinoma
|
August 9, 2023
Dr. Satkunasivam explains the momentum for an IO-plus-radiation strategy in MIBC, as well as the potential of sasanlimab.
View More
COXEN Model Determines Efficacy of Patient Response to Neoadjuvant Chemotherapy
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
July 28, 2023
The COXEN model is used to select genes for predicting tumor cell response to a specific drug treatment.
Read More
VESPER: 5-Year Overall Survival After Perioperative Chemotherapy Regimens for MIBC
Zachary Bessette
ASCO 2023
|
June 5, 2023
dd-MVAC provides a better OS at 5 years compared with GC in the perioperative setting for patients with MIBC.
Read More
Dr. Deek on the Prognostic Significance of Immune Cell Infiltration in MIBC
Matthew Deek, MD
ASCO 2023
|
June 4, 2023
Dr. Deek highlights his analysis of NRG RTOG 0524 and 0712 for prognostic significance of immune cell infiltration in MIBC.
View More
Infigratinib as Adjuvant Therapy for UC: Results From PROOF 302
Emily Menendez
ASCO 2023
|
June 1, 2023
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.
Read More
Drs. Koshkin, Basu on Clinical Practice Patterns for Adjuvant Therapy of ctDNA-Positive MIBC
Arnab Basu, MD, MPH, FACP
Advanced Urothelial Carcinoma
|
June 1, 2023
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
View More
Radical Cystectomy or Trimodality Therapy for MIBC: A Multi-institutional Analysis
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
May 23, 2023
Researchers compared maximal transurethral resection followed by concurrent chemoradiation with radical cystectomy.
Read More
RAIDER Trial Results Shed Light on Radiotherapy Toxicity Profiles, Adverse Events
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
May 18, 2023
A recent exploratory analysis examined patients with MIBC who were treated with radical radiotherapy and concomitant drugs.
Read More
Evaluating Quality of Life After Robot-Assisted Versus Open Radical Cystectomy
Akhil Abraham Saji, MD
Muscle Invasive Urothelial Carcinoma
|
May 1, 2023
The minimally invasive options available to patients diagnosed with muscle-invasive disease of urothelial origin are limited.
Read More
Utility of a ctDNA Assay in Patients With Node-Positive MIBC Receiving Neoadjuvant Chemotherapy
Zachary Bessette
AUA 2023: Focus on Bladder Cancer
|
April 28, 2023
A recent study correlated cell-free tumor DNA sequencing with response to neoadjuvant chemotherapy in patients with N+ MIBC.
Read More
TAR-200: Novel Drug Delivery System Aids Patients With MIBC
Emily Menendez
AUA 2023: Focus on Bladder Cancer
|
April 28, 2023
TAR-200 consists of a small silicone delivery system that provides sustained, local release of gemcitabine to the bladder.
Read More
RaDaR Sequencing Test Could Determine Possibility of Surgery for Patients With MIBC
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
March 23, 2023
The RaDar assay tracks up to 48 tumor-specific variants in cell-free DNA in a cancer patient’s blood plasma.
Read More
RETAIN: Risk-Enabled Therapy After Neoadjuvant Chemo for MIBC
Daniel M. Geynisman, MD
ASCO GU Symposium 2023
|
February 23, 2023
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
View More
HCRN GU 16-257: Neoadjuvant Therapy for Patients With MIBC
Matthew D. Galsky, MD
ASCO GU Symposium 2023
|
February 17, 2023
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.
View More
Intra-arterial Chemotherapy Plus Radiotherapy Versus Cystectomy for Patients With MIBC
Zachary Bessette
ASCO GU Symposium 2023
|
February 17, 2023
IAC-RT may be a useful and tolerable treatment option for patients with MIBC who are unfit for radical cystectomy.
Read More
Does Fragmented Care Result in Worse Outcomes for Patients With Bladder Cancer?
Emily Menendez
Muscle Invasive Urothelial Carcinoma
|
January 23, 2023
Researchers examined the impact of care fragmentation on patients receiving neoadjuvant chemotherapy and radical cystectomy.
Read More
Load More
Advertisement
Advertisement
Advertisement